On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor antibody screen on the Ortho Clinical Diagnostics VISION Analyzer. This instrumentation change was necessary as Ortho Clinical Diagnostics will be discontinuing support of the existing ProVue instrumentation in the future.
We will notify you of the transition date of our other four laboratories. To read more about this change, click here: Communications
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...